Read by QxMD icon Read

human papillomavirus vaccination

Loreto Fernández González
Cervical cancer is the fourth most common neoplasm in women worldwide and its incidence is associated with profound social inequities. In Chile, it is the second cause of death in women of reproductive age. The Chilean clinical guideline identifies the vaccine against Human Papillomavirus (HPV) as the main preventive measure. Since 2014, the Ministry of Health has implemented free immunization against HPV for girls and female adolescents. This article critically analyzes this public policy from the viewpoint of health equity, using as framework the Social Determinants of Health Model...
December 2017: Revista Médica de Chile
Rachael M Milwid, Federico Frascoli, Marc Steben, Jane M Heffernan
Human papillomavirus (HPV), a sexually transmitted infection, is the necessary cause of cervical cancer, the third most common cancer affecting women worldwide. Prevention and control strategies include vaccination, screening, and treatment. While HPV prevention and control efforts are important worldwide, they are especially important in low-income areas with a high infection rate or high rate of cervical cancer. This study uses mathematical modeling to explore various vaccination and treatment strategies to control for HPV and cervical cancer while using Nepal as a case study...
April 12, 2018: Bulletin of Mathematical Biology
Rayleen M Lewis, Lauri E Markowitz
BACKGROUND: Human papillomavirus (HPV) vaccination has been routinely recommended at age 11-12 years in the United States for females since 2006 and males since 2011. Coverage can be estimated using self/parent-reported HPV vaccination collected in the National Health and Nutrition Examination Survey (NHANES) for a wider age range than other national surveys. We assessed vaccination coverage in 2015-2016, temporal trends by age, and the validity of self/parent-reported vaccination status...
April 9, 2018: Vaccine
M Wallace, K Middelkoop, P Smith, C Pike, T Bennie, J Chandia, G Churchyard, G Gray, M H Latka, M Mathebula, M Nchabeleng, S Roux, C Slack, A Strode, L-G Bekker
BACKGROUND: HIV/AIDS remains a leading cause of death in adolescents (aged 15 - 25 years), and in sub-Saharan Africa HIV-related deaths continue to rise in this age group despite a decline in both adult and paediatric populations. This is attributable in part to high adolescent infection rates and supports the urgent need for more efficacious prevention strategies. In particular, an even partially effective HIV vaccine, given prior to sexual debut, is predicted to significantly curb adolescent infection rates...
March 28, 2018: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
Maria J Abou El-Ola, Mariam A Rajab, Dania I Abdallah, Ismail A Fawaz, Lyn S Awad, Hani M Tamim, Ahmad O Ibrahim, Anas M Mugharbil, Rima A Moghnieh
Background: Human papillomavirus (HPV) infection is an established predisposing factor of cervical cancer. In this study, we assessed the awareness about genital warts, cervical cancer, and HPV vaccine among mothers having girls who are at the age of primary HPV vaccination attending a group of schools in Lebanon. We also assessed the rate of HPV vaccination among these girls and the barriers to vaccination in this community. Subjects and methods: This is a cross-sectional, school-based survey...
2018: Therapeutics and Clinical Risk Management
Kate T McNair, Holly B Fontenot
Recent advances in human papillomavirus (HPV) science have led to updates to national HPV vaccine recommendations. This column takes a second look at two recent studies that provide evidence to support the current two-dose HPV vaccination schedule for youth ages 9 to 14 years. This short review will help nurses and other clinicians understand the health and economic benefits of the current dosing recommendation. Nurses are leaders in national vaccination efforts; therefore, it is vital that they remain up to date on the latest evidence that supports vaccination practice as well as health counseling and HPV vaccine recommendations...
April 2018: Nursing for Women's Health
Ashley Lacombe-Duncan, Peter A Newman, Philip Baiden
OBJECTIVE: Genital warts and human papillomavirus (HPV)-associated cancers in men can be substantially reduced through HPV vaccination; yet, globally, HPV vaccine uptake among boys remains low. This meta-ethnography synthesizes qualitative studies to understand, in-depth, HPV vaccine acceptability and decision-making among adolescent boys and/or their parents. METHODS: A systematic search identified qualitative studies examining HPV vaccines from the perspectives of boys and/or boys' parents...
April 3, 2018: Vaccine
Siok Shen Ng, Raymond Hutubessy, Nathorn Chaiyakunapruk
BACKGROUND: The success of human papillomavirus (HPV) national immunization program depends on effective strategies in optimizing the uptake of HPV vaccine. Given the increasing number of economic evaluations, this review was conducted to update the economic evidence on HPV vaccination, by focusing on: (i) 9-valent vaccine compared to bi- or quadrivalent vaccine; (ii) gender-neutral vaccination compared to female only vaccination; and (iii) multiple age cohort immunization compared to single age cohort immunization...
April 3, 2018: Vaccine
Jonah Musa
Although cervical cancer is a preventable cancer with a well-known natural history, it remains a huge burden in developing countries of sub-Saharan Africa where organized cervical cancer screening services are lacking. Developed countries that have invested on providing organized screening programs have made substantial progress in reducing both incidence and mortality due to cervical cancer. Implementing evidence-based interventions such as human papillomavirus (HPV) vaccination of young girls, early detection and treatment of premalignant conditions of the cervix through conventional Pap cytology, HPV screening or visual aided inspection with acetic acid could significantly reduce incidence of new cases at population level...
December 2017: African Journal of Reproductive Health
Sara E Oliver, Pamina Gorbach, Beau Gratzer, Martin Steinau, Tom Collins, Adam Parrish, Peter R Kerndt, Richard Crosby, Elizabeth R Unger, Lauri E Markowitz, Elissa Meites
BACKGROUND: Men who have sex with men (MSM) are at risk for cancers attributable to human papillomavirus (HPV), including oropharyngeal cancer. HPV vaccination is recommended for U.S. MSM through age 26 years. Oral HPV infection is associated with oropharyngeal cancer. We determined oral HPV prevalence and risk factors among young MSM. METHODS: The Young Men's HPV study enrolled MSM aged 18-26 years from clinics in Chicago and Los Angeles during 2012-2014. Participants self-reported demographics, sexual behaviors, vaccination and HIV status...
April 5, 2018: Sexually Transmitted Diseases
Annette H Sohn, Stephen J Kerr, Rawiwan Hansudewechakul, Sivaporn Gatechompol, Kulkanya Chokephaibulkit, Hanh Le Dung Dang, Dan Ngoc Hanh Tran, Jullapong Achalapong, Nipat Teeratakulpisarn, Amphan Chalermchockcharoenkit, Manopchai Thamkhantho, Tippawan Pankam, Thida Singtoroj, Wichai Termrungruanglert, Surasith Chaithongwongwatthana, Nittaya Phanuphak
Background: Infection with high-risk human papillomavirus (HR-HPV) may be higher in perinatally human immunodeficiency virus (HIV)-infected (PHIV) than HIV-uninfected (HU) adolescents because of long-standing immune deficiency. Methods: PHIV and HU females aged 12-24 years in Thailand and Vietnam were matched by age group and lifetime sexual partners. At enrollment, blood, cervical, vaginal, anal, and oral samples were obtained for HPV-related testing. The Wilcoxon and Fisher exact tests were used for univariate and logistic regression for multivariate analyses...
March 30, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
C Odoh, M Sanderson, E A Williams, P C Hull
OBJECTIVES: When examining vaccination coverage, researchers must make decisions about how to define outcome measures based on many factors, including the timing of doses. Different operationalizations of the same outcome can often lead to different findings and can affect the ability to make comparisons across studies. This methodological article aimed to illustrate the implications of two options for operationalizing human papillomavirus (HPV) vaccination based on timing: initiation of the first dose at any age vs before the 13th birthday (on time)...
March 30, 2018: Public Health
Funmilola T Odunyemi, Chizoma M Ndikom, O Abimbola Oluwatosin
Objective: The aim of this study is to evaluate the effect of nursing intervention on mothers' knowledge of cervical cancer and acceptance of human papillomavirus (HPV) vaccination for their adolescent daughters in Abuja, Nigeria. Methods: This was a quasi-experimental study that utilized two groups pre and post-test design. The study was carried out among civil servant mothers in Bwari (experimental group [EG]) and Kwali (control group[CG]) Area Councils of Abuja, Nigeria...
April 2018: Asia-Pacific Journal of Oncology Nursing
R I Henderson, M Shea-Budgell, C Healy, A Letendre, L Bill, B Healy, R A Bednarczyk, K Mrklas, C Barnabe, J Guichon, N Bedingfield, S MacDonald, A Colquhoun, S Glaze, T Nash, C Bell, J Kellner, R Richardson, T Dixon, J Starlight, G Runner, G Nelson
OBJECTIVE: In Canada, Indigenous people have higher human papillomavirus (HPV) infection rates, lower screening rates for cervical cancer, and higher rates of invasive cancer, leading to worse cervical cancer-related outcomes than observed in non-Indigenous Canadian women. Lingering harms from European colonization drive these health inequities and create public health challenges. Policy guidance is needed to optimize HPV vaccination rates and, thereby, decrease the burden of HPV-related illness, including high-morbidity surgical procedures and chemo-radiotherapy...
April 2018: Gynecologic Oncology
Renata Blatnik, Nitya Mohan, Maria Bonsack, Lasse G Falkenby, Stephanie Hoppe, Kathrin Josef, Alina Steinbach, Sara Becker, Wiebke M Nadler, Marijana Rucevic, Martin R Larsen, Mogjiborahman Salek, Angelika B Riemer
For rational design of therapeutic vaccines, detailed knowledge about target epitopes that are endogenously processed and truly presented on infected or transformed cells is essential. Many potential target epitopes, either of viral origin or mutation-derived, are presented at low abundance. Therefore, direct detection of these peptides remains a challenge. This study presents a method for the isolation and LC-MS3 -based targeted detection of low-abundant HLA class-I presented peptides from transformed cells...
March 30, 2018: Proteomics
Iacopo Baussano, Fulvio Lazzarato, Guglielmo Ronco, Silvia Franceschi
International variations in the prevalence of HPV infection derive from differences in sexual behaviors, which are also a key factor of the basic reproductive number (R0 ) of HPV infection in different populations. R0 affects the strength of herd protection and hence the impact of a vaccination program. Similar vaccination programs may therefore generate different levels of impact depending upon the population's pre-vaccination HPV prevalence. We used IARC's transmission model to estimate a) the overall effectiveness of vaccination versus no vaccination in women aged 15 to 34 years measured as percent prevalence reduction (%PR) of HPV16, and b) the corresponding herd protection in populations with gender-equal and traditional sexual behavior and with different levels of sexual activity, corresponding to pre-vaccination HPV16 prevalence from 1% to 8% as observed worldwide...
March 30, 2018: International Journal of Cancer. Journal International du Cancer
Ardashel Latsuzbaia, Marc Arbyn, Steven Weyers, Joël Mossong
BACKGROUND: In Luxembourg, a national Human Papillomavirus (HPV) vaccination programme was introduced in 2008, targeting 12-17 year old girls offering a choice of bivalent or quadrivalent vaccine free of charge. In 2015, the programme was changed offering the bivalent vaccine only to 11-13 year old girls. The aim of this study was to evaluate the HPV vaccination coverage, to assess the impact of age target changes and compare vaccination coverage to other European countries. METHODS: Anonymous HPV vaccination records consisting of individual vaccine doses obtained free of charge in pharmacies between 2008 and 2016 were extracted from the Luxembourgish Social Security database...
March 27, 2018: Vaccine
Rachael M Porter, Avnika B Amin, Robert A Bednarczyk, Saad B Omer
BACKGROUND AND OBJECTIVES: Vaccination with Human Papillomavirus (HPV) vaccine is recommended for 11-12 years-old, but uptake is suboptimal. Current messaging focuses on HPV infection transmission and prevention. Parents and providers are often uncomfortable discussing sexual practices of adolescents, contributing to the delay/refusal of vaccine. We created a cervical cancer-salient message encouraging HPV vaccination, emphasizing disease salience and disease threat, while promoting self-efficacy...
March 26, 2018: Vaccine
Abraham Degarege, Karl Krupp, Kristopher Fennie, Tan Li, Dionne P Stephens, Laura A V Marlow, Vijaya Srinivas, Anjali Arun, Purnima Madhivanan
OBJECTIVE: The aim of this study was to compare the parental attitudes and beliefs about HPV, cervical cancer and HPV vaccine between urban and rural areas, India. DESIGN: Cross sectional SETTING: Mysore, India PARTICIPANTS: Parents of school going adolescent girls INTERVENTION: Parents completed a self-administered questionnaire MAIN OUTCOME MEASURES: : Attitudes and beliefs about HPV, cervical cancer and HPV vaccine RESULTS: A total of 1609 parents from urban (n=778) and rural (n=831) areas participated in this study...
March 26, 2018: Journal of Pediatric and Adolescent Gynecology
Francesco Napolitano, Monica Navaro, Luigi Vezzosi, Gabriella Santagati, Italo Francesco Angelillo
This national online cross-sectional survey in Italy assessed primary care pediatricians' (PCPs) attitudes and practices regarding Human papillomavirus (HPV) vaccination and the contribution of several characteristics. The questionnaire was distributed from September 2016 to June 2017 to a random sample of 640 PCPs by email via an internet-link leading to a web-based survey platform (Lime Survey). Only 18.4% of PCPs always recommend the HPV vaccine to 11-12 year old boys. PCPs with longer practice activity, working in solo practice, always recommended the HPV vaccine to 11-12 year old girls, and believed that the vaccine was effective for boys were more likely to always recommend the HPV vaccine...
2018: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"